NJ State Employees Deferred Compensation Plan’s Acadia Pharmaceuticals ACAD Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17,000	Closed	-$363K	–	7
2025 Q3	$363K	Hold	17,000	–	–	0.04%	330
2025 Q2	$367K	Hold	17,000	–	–	0.04%	324
2025 Q1	$282K	Hold	17,000	–	–	0.04%	362
2024 Q4	$312K	Hold	17,000	–	–	0.04%	359
2024 Q3	$261K	Hold	17,000	–	–	0.03%	395
2024 Q2	$276K	Hold	17,000	–	–	0.03%	380
2024 Q1	$314K	Hold	17,000	–	–	0.04%	367
2023 Q4	$532K	Hold	17,000	–	–	0.07%	271
2023 Q3	$354K	Hold	17,000	–	–	0.05%	328
2023 Q2	$407K	Hold	17,000	–	–	0.06%	317
2023 Q1	$320K	Hold	17,000	–	–	0.05%	363
2022 Q4	$271K	Hold	17,000	–	–	0.04%	380
2022 Q3	$278K	Hold	17,000	–	–	0.05%	368
2022 Q2	$240K	Hold	17,000	–	–	0.04%	397
2022 Q1	$412K	Hold	17,000	–	–	0.06%	334
2021 Q4	$397K	Hold	17,000	–	–	0.05%	349
2021 Q3	$282K	Hold	17,000	–	–	0.04%	412
2021 Q2	$415K	Hold	17,000	–	–	0.06%	337
2021 Q1	$439K	Hold	17,000	–	–	0.06%	329
2020 Q4	$909K	Hold	17,000	–	–	0.14%	149
2020 Q3	$701K	Hold	17,000	–	–	0.13%	166
2020 Q2	$824K	Hold	17,000	–	–	0.15%	132
2020 Q1	$718K	Hold	17,000	–	–	0.16%	127
2019 Q4	$727K	Hold	17,000	–	–	0.12%	169
2019 Q3	$612K	Hold	17,000	–	–	0.11%	185
2019 Q2	$454K	Sell	17,000 -4,000	-19%	-$102K	0.08%	300
2019 Q1	$564K	Hold	21,000	–	–	0.1%	218
2018 Q4	$340K	Sell	21,000 -11,000	-34%	-$214K	0.07%	339
2018 Q3	$664K	Sell	32,000 -8,000	-20%	-$126K	0.11%	214
2018 Q2	$611K	Buy	+40,000	New	+$713K	0.11%	247

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's ACAD Position: Q4 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 17,000 shares — an estimated $363K sold.

NJ State Employees Deferred Compensation Plan first reported a position in ACAD in Q2 2018 and held it in 30 quarters. The position peaked at $909K in Q4 2020. 335 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

NJ State Employees Deferred Compensation Plan reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 17,000 Acadia Pharmaceuticals shares in Q4 2025, an estimated $363K.
NJ State Employees Deferred Compensation Plan first reported a position in Acadia Pharmaceuticals in Q2 2018 and held it in 30 quarters.
NJ State Employees Deferred Compensation Plan's Acadia Pharmaceuticals position peaked at $909K in Q4 2020.
335 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2025.